Search - tctmd.com

Displaying 41 - 60 of 63

Sort: Relevancy | Date

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

Todd Neale

October 07, 2022

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Conference News EuroPCR 2022

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

Michael O'Riordan

May 20, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Shelley Wood

May 09, 2019

Advertisement

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Modified Surgical MV Repair Stands Up to Replacement

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

‘Enormous’ QoL Improvements With Mavacamten in HCM

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content